- Home
- RCKY vs ATNM Comparison
RCKY vs ATNM Comparison
Compare RCKY & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- ATNM
- Stock Information
- Founded
- RCKY 1932
- ATNM 2000
- Country
- RCKY United States
- ATNM United States
- Employees
- RCKY N/A
- ATNM N/A
- Industry
- RCKY Shoe Manufacturing
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- ATNM Health Care
- Exchange
- RCKY Nasdaq
- ATNM Nasdaq
- Market Cap
- RCKY 222.9M
- ATNM 56.5M
- IPO Year
- RCKY 1993
- ATNM N/A
- Fundamental
- Price
- RCKY $30.06
- ATNM $1.73
- Analyst Decision
- RCKY Hold
- ATNM Strong Buy
- Analyst Count
- RCKY 2
- ATNM 5
- Target Price
- RCKY $28.00
- ATNM $14.20
- AVG Volume (30 Days)
- RCKY 36.2K
- ATNM 285.8K
- Earning Date
- RCKY 10-30-2024
- ATNM 10-31-2024
- Dividend Yield
- RCKY 2.06%
- ATNM N/A
- EPS Growth
- RCKY 60.94
- ATNM N/A
- EPS
- RCKY 1.99
- ATNM N/A
- Revenue
- RCKY $462,730,000.00
- ATNM $81,000.00
- Revenue This Year
- RCKY $1.34
- ATNM $186.10
- Revenue Next Year
- RCKY $5.68
- ATNM $19,248.94
- P/E Ratio
- RCKY $15.10
- ATNM N/A
- Revenue Growth
- RCKY N/A
- ATNM 80.00
- 52 Week Low
- RCKY $11.78
- ATNM $1.33
- 52 Week High
- RCKY $40.14
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- RCKY 47.88
- ATNM 41.48
- Support Level
- RCKY $29.18
- ATNM $1.48
- Resistance Level
- RCKY $30.44
- ATNM $1.80
- Average True Range (ATR)
- RCKY 0.80
- ATNM 0.12
- MACD
- RCKY -0.05
- ATNM 0.04
- Stochastic Oscillator
- RCKY 31.10
- ATNM 54.44
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract. It generates majority of the revenue from Wholesale segment.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.